Top

Published in:

01-09-2006 | Case Report

Rasburicase treatment in severe tophaceous gout: a novel therapeutic option

Authors: J. D. Moolenburgh, M. K. Reinders, T. L. Th. A. Jansen

Published in: Clinical Rheumatology | Issue 5/2006

Abstract

We recently encountered a destructive case of tophaceous gout in a 57-year-old patient. Despite perfect therapy compliance, the patient failed in the conventional urate-lowering treatment, accounting for the ongoing urate retention and accumulation with progressive tophaceous bulky disease. Application of an experimental scheme of uricolytical therapy on this patient was able to reduce bulky disease significantly. In modern medicine, potent urate-debulking medication with urate oxidase (uricase) derivatives is at our disposal, and it is a challenge for rheumatologists to install the right strategy including innovative approaches with potent uricolytic therapy on the right patient at the right time.

Fam AG (1999) Hyperuricemia and gout. In: Rakel RE (ed) Conn's current therapy, 51st edn. Saunders, Philadelphia, pp 561–566

Emmerson BT (1996) The management of gout. N Engl J Med 334:445–451CrossRefPubMed

Terkeltaub RA (2003) Gout. N Engl J Med 349(17):1647–1655CrossRefPubMed

Bieber JD, Terkeltaub RA (2004) Gout; on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 50(8):2400–2414CrossRefPubMed

Perez-Ruiz F, Alonzo-Ruiz A, Calabozo M et al (1998) Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57:545–549PubMedCrossRef

Jansen TLThA, Reinders MK, Van Roon EN, Brouwers JRBJ (2004) Benzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”? Clin Exp Rheumatol 22(5):651PubMed

Tausche AK, Richter K, Grässler A, Hänsel S, Roch B, Schröder HE (2004) Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis 63:1351–1352CrossRefPubMed

Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350(11):1093–1103CrossRefPubMed

Davidson MB, Thakkar S, Hix JK et al (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116:546–555CrossRefPubMed

10.

Rozenberg S, Roch B, Dorent R, Koeger AC, Borget Wrona N, Bourgeois P (1995) Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum (Engl Ed) 62(5):392–394PubMed

11.

Loeb JN (1972) The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 15:189–192PubMedCrossRef

12.

Seegmiller JE (1965) The acute attack of gouty arthritis. Arthritis Rheum 8:714–723PubMedCrossRef

13.

Li-Yu J, Clayburne G, Sieck M et al (2001) Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28:577–580PubMed

14.

Mc Carty DJ (1994) Gout without hyperuricemia. JAMA 271:302–303CrossRefPubMed

15.

Ferraz MB, O'Brien B (1995) A cost effective analysis of urate lowering drugs in non-tophaceous recurrent gouty arthritis. J Rheumatol 22:908–914PubMed

Title: Rasburicase treatment in severe tophaceous gout: a novel therapeutic option
Authors: J. D. Moolenburgh
M. K. Reinders
T. L. Th. A. Jansen
Publication date: 01-09-2006
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 5/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-005-0043-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2006

Infection and work stress are potential triggers of ankylosing spondylitis

A therapeutic education and functional readaptation program for Spanish patients with musculoskeletal chronic diseases

Sjögren syndrome in a child: favorable response of the arthritis to TNFα blockade

Human foamy virus bel1 sequence in patients with autoimmune rheumatic diseases

Osteoarthritis is for the birds

MRI appearance of retrocalcaneal bursitis and rheumatoid nodule in a patient with rheumatoid arthritis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials